팝업레이어 알림
About Rznomics
Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.
About Rznomics
Excellence in Technology
-
Dual function in a single molecule
-
Modular Engineering
-
Disease-related RNA target specificity
-
High Performance
-
Continuous regulation of gene expression
Rznomics Pipeline
PIPELINE
Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform
technology for cancer/intractable diseases.
NEWS & PRESS
Latest news about Rznomics or Stay informed about Rznomics
-
Rznomics Passed Technology Evaluation, Advancing Toward KOSDAQ Lis...
- Received “A, A” ratings from two technology evaluation institutions designated by the Korea E...
-
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-...
Co-development of precision RNA therapeutics for inherited hearing loss treatmentRznomics Inc., a S...
-
Rznomics Develops the World’s First RNA Editing Therapy: “TSR ...
Rznomics develops anticancer drug and rare disease therapies using the world’s first RNA editing...
- Head Office #801 Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- Research Institute#803(Research Institute) Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
